Editor’s note: James Veltrop’s clients do not include Ranbaxy Labs.
When Teva Pharmaceuticals Industries Ltd. secured the rights to market a generic version of the blockbuster drug Neurontin in 2004, it looked like the company was in for a period of robust good health. After all, the brand-name version of the drug, used both to treat epilepsy and as a pain reliever, had generated more than $2 billion in sales for Pfizer Inc. in 2003. The generic version (gabapentin) was supposed to bring in hundreds of millions for Teva.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
For questions call 1-877-256-2472 or contact us at [email protected]